Developer docs
API playgroundTry for free, no card

Search company profiles

Medios

Full company profile

uuid000r5vy

Namestring
Medios
Legal namestring
Medios AG
Websiteurl
medios.ag
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Medios AG is a Berlin-headquartered, Frankfurt-listed specialty pharmaceutical company that manufactures and distributes patient-individualized medicines, with FY2025 revenue exceeding €2.0 billion and operations spanning Germany, the Netherlands, Belgium, and Spain. The company operates two divisions: Specialty Pharma, which combines pharmaceutical wholesale, GMP-certified patient-specific drug compounding, and cold-chain distribution of high-value therapies (primarily oncology, immunology, and biologics) for partner pharmacies, clinics, and pharmaceutical manufacturers; and Advanced Therapies, a strategic initiative focused on biotechnological precision medicine. Revenue is generated principally through transaction-fee wholesale distribution and GMP compounding services, supplemented by a digital service infrastructure that provides workflow and traceability tools to pharmacy and clinic partners.

The business model is B2B enterprise field sales targeting specialty pharmacies, clinics, pharmaceutical manufacturers, and clinical study sponsors under Germany's regulated reimbursement framework. The platform is vertically integrated across procurement, quality assurance, GMP compounding, cold-chain logistics, and digital workflow tools, serving as critical last-mile infrastructure for personalized medicine in Germany. Go-to-market is relationship-driven, with pricing obtained via direct sales engagement rather than published rates, and customer base distributed across many partner pharmacies and institutions.

Medios has executed a deliberate European platform strategy: the June 2024 close of the Ceban Pharmaceuticals B.V. acquisition (€235.3M cash plus 1.7M shares) added compounding operations in the Netherlands, Belgium, and Spain; founder Manfred Schneider sold a 14.9% stake to Luxempart S.A. to support internationalization; and a January 2026 exclusive distribution partnership with Bedrocan extended reach into medical cannabis with stated plans to expand into Austria, Belgium, Italy, and Spain. Defensive actions have accompanied expansion: the Aschaffenburg production site (~10% of German volume, 32 staff) was closed in mid-2026 to consolidate patient-individual manufacturing amid regulatory and pricing pressure, and FY2026 adjusted EBITDA guidance was cut to €88-92M from €94-102M while revenue guidance was raised to €2.10-2.16B, reflecting a margin-protection posture alongside top-line growth.

Short descriptiontext

Medios AG is a Berlin-based specialty pharmaceutical company that manufactures and distributes patient-individualized medications, operates GMP-certified compounding facilities, and serves specialty pharmacies, clinics, and pharmaceutical manufacturers across Germany and Europe.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersBerlin, Germany
HQ citystring
Berlin
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, patient-specific medicines, pharmaceutical compounding services, individualized oncology therapies, cold-chain drug distribution
Industry3 codes
PRIMARYCRAOAHAD
Specialty Pharmacy & Biologics Distribution
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Supply (Specialty Pharma Trading)
TypeTransaction Fee
Description

Wholesale distribution of high-value specialty pharmaceuticals to partner pharmacies and clinics across Germany. This includes procurement, quality assurance, and distribution of specialty drugs for complex diseases.

finanznachrichten.de
2Drug Compounding Services
TypeTransaction Fee
Description

GMP-certified patient-specific compounding and manufacturing services for individualized medications, primarily serving oncology, immunology, and biologic treatment markets.

ad-hoc-news.de
3Digital Service Infrastructure
TypeManaged Services
Description

Digital service infrastructure for pharmacy and clinic workflows, providing integration and operational support services.

ad-hoc-news.de
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Medios AG manufactures and supplies patient-specific medicinal products through pharmaceutical wholesale, GMP-certified drug compounding for individualized therapies, and cold-chain distribution. The company serves specialty pharmacies, clinics, and pharmaceutical manufacturers across Germany and Europe with a focus on oncology, immunology, and biologic treatments. Operating as a vertically integrated specialty pharma platform, Medios combines procurement, quality assurance, GMP-certified manufacturing, and digital traceability to support personalized medicine delivery.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Record H1 2026 revenue of €1,075 million, up from €991.7 million in H1 2025
+1 more record
Product overview1 text field

Medios AG operates as a vertically integrated specialty pharma platform combining pharmaceutical wholesale, GMP-certified patient-specific drug compounding, and digital distribution services for high-cost therapies. The platform spans two core divisions: Specialty Pharma (drug supply, patient-individual compounding, and distribution for oncology and autoimmune disorders) and Advanced Therapies (biotechnology precision medicine). The company serves manufacturers, specialty pharmacies, clinics, and pharmaceutical companies across Germany and Europe, supporting its partner-first integration model with cold-chain logistics and digital service infrastructure.

Product and service3 records
1Specialty Pharma
CategorySpecialty Pharmaceutical Distribution
Description

Pharmaceutical wholesale, drug procurement, quality assurance, and distribution of high-value specialty medications for specialty pharmacies, clinics, and pharmaceutical companies. Includes cold-chain logistics and patient-individual manufacturing operations.

2Advanced Therapies
CategoryBiotechnology / Precision Medicine
Description

Cutting-edge biotechnological precision medicine and advanced therapy products representing the company's strategic initiative in biotechnology-based treatments.

3GMP-Certified Compounding Services
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-20
Description

Exclusive distribution partnership for medicinal cannabis products. Medios appointed as exclusive distribution partner for Bedrocan's products in Germany, with plans to expand to Austria, Belgium, Italy, and Spain. Medios distributes cannabis produced at Bedrocan's EU-GMP certified facility in Denmark, leveraging existing Cannaflos network for seamless transition. Partnership streamlines procurement for German pharmacists who previously navigated fragmented distribution markets.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-18
Description

Acquisition of Ceban Pharmaceuticals B.V., a leading Dutch pharmaceutical compounding platform with operations in Belgium and Spain. Deal involved €235.3 million cash component and 1.7 million Medios shares. Part of strategy to build a European Specialty Pharma platform, expected to significantly boost revenue and profitability by 2024 and 2025. Acquisition completed in June 2024.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Aenova is one of Europe's largest CDMOs offering solid, semi-solid, liquid, sterile, and biological contract manufacturing services from multiple European sites. Comparable to Medios's GMP-certified compounding and manufacturing operations for high-value drugs, though more diversified across dosage forms.

TypeDirect peer
Description

NextPharma is a European specialty CDMO focused on sterile liquids, semi-solids, and patient-specific manufacturing across multiple European sites. Directly comparable to Medios's GMP-certified patient-specific compounding and sterile manufacturing capabilities for specialty drugs.

TypeDirect peer
Description

Stada is a major German specialty pharmaceutical company with operations in generics, specialty pharma, and consumer health, including compounding and distribution. Comparable to Medios as a Germany-based specialty pharma platform with focus on niche/individualized medicines.

TypeDirect peer
Description

Dermapharm is a German specialty pharmaceutical manufacturer focused on niche/rare disease products and parallel imports. Comparable to Medios's specialty pharma strategy targeting smaller patient populations with high-value therapies, though with more emphasis on dermatology and rare disease.

TypeDirect peer
Description

Sanacorp is Germany's largest pharmaceutical wholesale cooperative serving pharmacies with a broad portfolio including specialty drugs. Directly comparable to Medios's pharmaceutical wholesale and distribution activities to German pharmacies, though without the compounding specialization.

6Recipharm AB
TypeBroad incumbent
Description

Recipharm is a major European CDMO offering a broad range of pharmaceutical contract manufacturing services across multiple dosage forms and technologies. Comparable to Medios's GMP manufacturing footprint, though much larger and broader in scope (lacks the specialty pharmacy distribution angle).

TypeDirect peer
Description

PharmaZell (now part of SEQENS) is a European specialty API and CDMO with focus on niche molecules and complex manufacturing. Comparable to Medios's specialty pharma positioning, particularly in patient-specific and complex therapies, though concentrated on APIs and complex small molecules.

8Alliance Healthcare (Walgreens Boots Alliance)
TypeBroad incumbent
Description

Alliance Healthcare is a major European pharmaceutical wholesaler and distributor serving pharmacies across multiple countries. Comparable to Medios's wholesale distribution business, but at much greater scale and without the GMP compounding vertical.

9Polpharma
TypeRegional player
Description

Polpharma is the largest Polish pharmaceutical manufacturer and a leading Central/Eastern European specialty pharma player. Comparable to Medios's specialty pharma manufacturing and distribution model, though primarily serving Polish and CEE markets.

TypeDirect peer
Description

Hameln Pharma (now part of Piramal) is a German specialty CDMO specializing in sterile injectables, ampoules, and complex injectable formulations. Directly comparable to Medios's GMP-certified sterile compounding capabilities, particularly for oncology and individualized injectable therapies.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Medios

Specialty Pharmaceuticalsmedios.ag

Medios AG is a Berlin-based specialty pharmaceutical company that manufactures and distributes patient-individualized medications, operates GMP-certified compounding facilities, and serves specialty pharmacies, clinics, and pharmaceutical manufacturers across Germany and Europe.

What Medios does

Medios AG is a Berlin-headquartered, Frankfurt-listed specialty pharmaceutical company that manufactures and distributes patient-individualized medicines, with FY2025 revenue exceeding €2.0 billion and operations spanning Germany, the Netherlands, Belgium, and Spain. The company operates two divisions: Specialty Pharma, which combines pharmaceutical wholesale, GMP-certified patient-specific drug compounding, and cold-chain distribution of high-value therapies (primarily oncology, immunology, and biologics) for partner pharmacies, clinics, and pharmaceutical manufacturers; and Advanced Therapies, a strategic initiative focused on biotechnological precision medicine. Revenue is generated principally through transaction-fee wholesale distribution and GMP compounding services, supplemented by a digital service infrastructure that provides workflow and traceability tools to pharmacy and clinic partners.

The business model is B2B enterprise field sales targeting specialty pharmacies, clinics, pharmaceutical manufacturers, and clinical study sponsors under Germany's regulated reimbursement framework. The platform is vertically integrated across procurement, quality assurance, GMP compounding, cold-chain logistics, and digital workflow tools, serving as critical last-mile infrastructure for personalized medicine in Germany. Go-to-market is relationship-driven, with pricing obtained via direct sales engagement rather than published rates, and customer base distributed across many partner pharmacies and institutions.

Medios has executed a deliberate European platform strategy: the June 2024 close of the Ceban Pharmaceuticals B.V. acquisition (€235.3M cash plus 1.7M shares) added compounding operations in the Netherlands, Belgium, and Spain; founder Manfred Schneider sold a 14.9% stake to Luxempart S.A. to support internationalization; and a January 2026 exclusive distribution partnership with Bedrocan extended reach into medical cannabis with stated plans to expand into Austria, Belgium, Italy, and Spain. Defensive actions have accompanied expansion: the Aschaffenburg production site (~10% of German volume, 32 staff) was closed in mid-2026 to consolidate patient-individual manufacturing amid regulatory and pricing pressure, and FY2026 adjusted EBITDA guidance was cut to €88-92M from €94-102M while revenue guidance was raised to €2.10-2.16B, reflecting a margin-protection posture alongside top-line growth.

Medios firmographics

Firmographics
Name
Medios
Legal name
Medios AG
Website
https://medios.ag
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Medios AG is a Berlin-based specialty pharmaceutical company that manufactures and distributes patient-individualized medications, operates GMP-certified compounding facilities, and serves specialty pharmacies, clinics, and pharmaceutical manufacturers across Germany and Europe.
Ownership category
akta.pro rank

Medios industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYCRAOAHAD
Specialty Pharmacy & Biologics Distribution
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Specialty pharmaceuticals
  • Patient-specific medicines
  • Pharmaceutical compounding services
  • Individualized oncology therapies
  • Cold-chain drug distribution

Where Medios is headquartered

Location

Headquarters

HQ city
Berlin
HQ country
Germany
HQ region
Europe

Offices5 records

Markets served

Medios business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Pharmaceutical Supply (Specialty Pharma Trading): Wholesale distribution of high-value specialty pharmaceuticals to partner pharmacies and clinics across Germany. This includes procurement, quality assurance, and distribution of specialty drugs for complex diseases.
  2. Drug Compounding Services: GMP-certified patient-specific compounding and manufacturing services for individualized medications, primarily serving oncology, immunology, and biologic treatment markets.
  3. Digital Service Infrastructure: Digital service infrastructure for pharmacy and clinic workflows, providing integration and operational support services.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Medios product offering

Product offering

Core offering

Medios AG manufactures and supplies patient-specific medicinal products through pharmaceutical wholesale, GMP-certified drug compounding for individualized therapies, and cold-chain distribution. The company serves specialty pharmacies, clinics, and pharmaceutical manufacturers across Germany and Europe with a focus on oncology, immunology, and biologic treatments. Operating as a vertically integrated specialty pharma platform, Medios combines procurement, quality assurance, GMP-certified manufacturing, and digital traceability to support personalized medicine delivery.

Product overview

Medios AG operates as a vertically integrated specialty pharma platform combining pharmaceutical wholesale, GMP-certified patient-specific drug compounding, and digital distribution services for high-cost therapies. The platform spans two core divisions: Specialty Pharma (drug supply, patient-individual compounding, and distribution for oncology and autoimmune disorders) and Advanced Therapies (biotechnology precision medicine). The company serves manufacturers, specialty pharmacies, clinics, and pharmaceutical companies across Germany and Europe, supporting its partner-first integration model with cold-chain logistics and digital service infrastructure.

Differentiator

Problem solved

Functional benefit

Products and services

  • Specialty Pharma Pharmaceutical wholesale, drug procurement, quality assurance, and distribution of high-value specialty medications for specialty pharmacies, clinics, and pharmaceutical companies. Includes cold-chain logistics and patient-individual manufacturing operations.
  • Advanced Therapies Cutting-edge biotechnological precision medicine and advanced therapy products representing the company's strategic initiative in biotechnology-based treatments.
  • GMP-Certified Compounding Services

Quantifiable outcome

  • Record H1 2026 revenue of €1,075 million, up from €991.7 million in H1 2025
  • +1 more outcomes

Companies that use Medios

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Medios technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Medios partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • BedrocancoreStrategic or Co-development Partner · 20 January 2026Exclusive distribution partnership for medicinal cannabis products. Medios appointed as exclusive distribution partner for Bedrocan's products in Germany, with plans to expand to Austria, Belgium, Italy, and Spain. Medios distributes cannabis produced at Bedrocan's EU-GMP certified facility in Denmark, leveraging existing Cannaflos network for seamless transition. Partnership streamlines procurement for German pharmacists who previously navigated fragmented distribution markets.
  • Ceban Pharmaceuticals B.V.coreStrategic or Co-development Partner · 18 March 2024Acquisition of Ceban Pharmaceuticals B.V., a leading Dutch pharmaceutical compounding platform with operations in Belgium and Spain. Deal involved €235.3 million cash component and 1.7 million Medios shares. Part of strategy to build a European Specialty Pharma platform, expected to significantly boost revenue and profitability by 2024 and 2025. Acquisition completed in June 2024.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Medios competitors and assessment

Company assessment

Direct peers

  • Aenova Group: Aenova is one of Europe's largest CDMOs offering solid, semi-solid, liquid, sterile, and biological contract manufacturing services from multiple European sites. Comparable to Medios's GMP-certified compounding and manufacturing operations for high-value drugs, though more diversified across dosage forms.
  • NextPharma: NextPharma is a European specialty CDMO focused on sterile liquids, semi-solids, and patient-specific manufacturing across multiple European sites. Directly comparable to Medios's GMP-certified patient-specific compounding and sterile manufacturing capabilities for specialty drugs.
  • Stada Arzneimittel AG: Stada is a major German specialty pharmaceutical company with operations in generics, specialty pharma, and consumer health, including compounding and distribution. Comparable to Medios as a Germany-based specialty pharma platform with focus on niche/individualized medicines.
  • Dermapharm Holding SE: Dermapharm is a German specialty pharmaceutical manufacturer focused on niche/rare disease products and parallel imports. Comparable to Medios's specialty pharma strategy targeting smaller patient populations with high-value therapies, though with more emphasis on dermatology and rare disease.
  • Sanacorp eG: Sanacorp is Germany's largest pharmaceutical wholesale cooperative serving pharmacies with a broad portfolio including specialty drugs. Directly comparable to Medios's pharmaceutical wholesale and distribution activities to German pharmacies, though without the compounding specialization.
  • PharmaZell (SEQENS): PharmaZell (now part of SEQENS) is a European specialty API and CDMO with focus on niche molecules and complex manufacturing. Comparable to Medios's specialty pharma positioning, particularly in patient-specific and complex therapies, though concentrated on APIs and complex small molecules.
  • Hameln Pharma (Piramal Pharma Solutions): Hameln Pharma (now part of Piramal) is a German specialty CDMO specializing in sterile injectables, ampoules, and complex injectable formulations. Directly comparable to Medios's GMP-certified sterile compounding capabilities, particularly for oncology and individualized injectable therapies.

Broad incumbents

  • Recipharm AB: Recipharm is a major European CDMO offering a broad range of pharmaceutical contract manufacturing services across multiple dosage forms and technologies. Comparable to Medios's GMP manufacturing footprint, though much larger and broader in scope (lacks the specialty pharmacy distribution angle).
  • Alliance Healthcare (Walgreens Boots Alliance): Alliance Healthcare is a major European pharmaceutical wholesaler and distributor serving pharmacies across multiple countries. Comparable to Medios's wholesale distribution business, but at much greater scale and without the GMP compounding vertical.

Regional players

  • Polpharma: Polpharma is the largest Polish pharmaceutical manufacturer and a leading Central/Eastern European specialty pharma player. Comparable to Medios's specialty pharma manufacturing and distribution model, though primarily serving Polish and CEE markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Medios social profiles

Digital presence

Medios financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Medios leadership team

Management profile

Number of profiles

Profiles1 record

Medios subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Medios funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Medios M&A and investment

M&A and investment

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medios

What does Medios do?

Medios AG manufactures and supplies patient-specific medicinal products through pharmaceutical wholesale, GMP-certified drug compounding for individualized therapies, and cold-chain distribution. The company serves specialty pharmacies, clinics, and pharmaceutical manufacturers across Germany and Europe with a focus on oncology, immunology, and biologic treatments. Operating as a vertically integrated specialty pharma platform, Medios combines procurement, quality assurance, GMP-certified manufacturing, and digital traceability to support personalized medicine delivery.

Is Medios a public or private company?

Medios is a public company. It is classified as public and is currently operating.

When was Medios founded?

Medios was founded in 2015. It employs 1,001 to 5,000 people.

Where is Medios based?

Medios is headquartered in Berlin, Germany, in the Europe region.

How does Medios make money?

Three revenue lines are on record. Pharmaceutical Supply (Specialty Pharma Trading) is the primary driver. The others are drug Compounding Services and digital Service Infrastructure.

Who are Medios's main competitors?

Direct peers on record are Aenova Group, NextPharma, Stada Arzneimittel AG, Dermapharm Holding SE, Sanacorp eG, PharmaZell (SEQENS) and Hameln Pharma (Piramal Pharma Solutions). Broad incumbents are Recipharm AB and Alliance Healthcare (Walgreens Boots Alliance). Polpharma is listed as a regional player.

Does Medios have an API?

No public API is recorded for Medios.

What industry is Medios in?

Medios's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is CRAOAHAD, Specialty Pharmacy & Biologics Distribution, with a secondary code of HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO. Its NAICS code is 325412 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinanzNachrichten.deMedios-Aktie schießt hoch: Beginnt jetzt die große Rallye?Medios AG's stock rose over 9% on Thursday after announcing a new share buyback program. The Berlin-based pharmaceutical specialist will invest millions in its own shares, following months of downward pressure. Investors now question whether this marks a sustainable trend reversal.Investing.comWhy is Medios stock sliding today?Medios AG stock fell 2.2% to €10.62 on the first day of its share buyback program, which failed to generate fresh buying momentum. The program repurchases up to 1.5 million shares (5.88% of capital) for up to €19 million, with execution starting today. The decline reflects profit-taking and broader German market weakness.Investing.comMedios shares jump 8% after new buyback program announcedMedios AG shares rose 8% after the company announced a new share buyback program valued at up to 19 million euros. The program will repurchase up to 1.5 million shares over up to twelve months, starting Thursday. Repurchased shares may be used for acquisitions, employee stock plans, or stock-based compensation.FinanzNachrichten.deEQS-CMS: Medios AG: Erwerb eigener AktienMedios AG announced a share buyback program starting 19 November 2026, to be completed by 19 November 2027. The program covers up to 1.5 million shares, valued at up to EUR 19 million, with purchases made via Xetra. The board exercised its authorization from the June 2026 general meeting.Business & FinancialMedios Approves New Share Buyback ProgramMedios AG approved a new share buyback program, part of its "Medios Next Level" strategy. The repurchased shares can be used for acquisitions, employee stock plans, or stock-based compensation. The company will retire treasury shares from the 2025 program to reduce outstanding shares.The future of tradingMontega Rates Medios Buy With EUR 23 Price TargetMontega reiterated a buy rating on Medios on Nov. 11, 2026, with a 12-month price target of EUR 23. Third-quarter revenue rose 3.7% year over year to EUR 558.1 million, slightly exceeding forecasts, while adjusted EBITDA fell short. Full-year guidance was confirmed at the lower end of the range.Seeking AlphaMedios AG (MEDOF) Q3 2026 Earnings Call TranscriptMedios AG reported first nine months revenue of EUR 1.63 billion, up 6.7%, with EBITDA of EUR 66.7 million and EPS of EUR 1.35. The company maintained its full-year estimates despite special events affecting operating cash flow.FinanzNachrichten.deAktien Frankfurt: Weiter auf Erholungskurs - Dax flirtet mit RekordhochGerman stocks rose on Tuesday, with the Dax at 26,573, 1.2% higher, as falling oil prices helped. Infineon and Henkel gained, while K+S and Medios fell after quarterly results. Analysts expect Infineon's growth to continue.